Options for induction immunosuppression in liver transplant recipients

Drugs

Volumn 62, Issue 7, 2002, Pages 995-1011

  Moser, Michael A J ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPHENHYDRAMINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; POLYCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; TACROLIMUS;

BONE MARROW TOXICITY; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG SAFETY; DRUG SPECIFICITY; GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY FAILURE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; POSTOPERATIVE COMPLICATION; REVIEW; TREATMENT PLANNING;

HEPATITIS C VIRUS;

EID: 0036091225     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262070-00002     Document Type: Review

References (76)

1. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome
2. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression
3. Analysis of late deaths after liver transplantation
4. Use of antilymphocyte induction therapy in liver transplantation
5. Cyclosporine
6. A comparison of the renal effects of tacrolimus and cyclosporine in patients with liver transplants
7. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection
8. A pilot study of immunosuppression monotherapy in liver transplantation: Tacrolimus vs. microemulsion cyclosporine
9. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation
10. Clinical use of tacrolimus in liver transplantation
11. Tacrolimus-based immunosuppression after liver transplantation: A randomized study comparing dual versus triple low-dose oral regimens
12. Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation
13. A prospective study comparing the safety and efficacy of mycophenolate mofetil vs. azathioprine in primary liver transplant recipients
14. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients
15. A prospective randomized trial of mycophenolate mofetil with Neoral or tacrolimus after orthotopic liver transplantation
16. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK506 than in combination with cyclosporine A
17. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation
18. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients
19. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation
20. RS-61443: A new immunosuppressive agent
21. Mycophenolate mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation
22. Mycophenolate mofetil as induction therapy after liver transplantation
23. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
24. A standardized ALG for use in man
25. Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection
26. Monoclonal antibodies defining distinctive human T-cell surface antigens
27. OKT3 first close reaction: Association with the T-cell subsets and cytokine release
28. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation
29. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients
30. A randomized trial of OKT3 based vs. cyclosporine based immunoprophylaxis after liver transplantation
31. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation: A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1
32. Interluekin-2 receptor antibody versus antithymocyte globulin as part of quadruple induction therapy after orthotopic liver transplantation: A randomized study
33. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation
34. Experience with daclizumab in liver transplantation. Renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation
35. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients
36. Daclizumab induction in liver transplant recipients
37. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function
38. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients
39. Immunoprophylaxis with Simulect® (basiliximab) in combination with cyclosporine A and steroids in liver transplantation
40. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial
41. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant patients
42. Interleukin-2 receptor targeted therapy- rationale and applications in organ transplantation
43. Anti CD25 monoclonal antibody prevents early rejection in liver transplantation - A pilot study
44. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation
45. A humanized antibody that binds to the interleukin-2 receptor
46. Basiliximab
47. Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients
48. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation
49. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation
50. Reduction of acute renal allograft rejection by daclizumab
51. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation
52. Disposition and immunodynamics of basiliximab in liver allograft recipients
53. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation
54. Can antibody prophylaxis allow sparing of other immunosuppression?
55. Sirolimus-tacrolimus combination immunosuppression
56. Use OKT3 is associated with the early and severe recurrence of hepatitis C after liver transplantation
57. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney diseases liver transplantation database
58. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation
59. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C - A preliminary report of a prospective randomized trial
60. Transplantation for fulminant hepatic failure: Comparing tacrolimus vs. cyclosporine for immunosuppression and the outcome in elective transplants
61. Severe or multiple rejection episodes are associated with earlier recurrence of hepatitis C after orthotopic liver transplantation
62. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
63. Orthotopic liver transplantation for hepatitis C: Outcome, effects of immunosuppression, and causes of retransplantation during an eight-year single center experience
64. Natural history of recurrence of hepatitis C in liver transplant recipients under mycophenolate mofetil immunosuppression
65. A prospective randomised trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
66. Liver transplantation with a steroid-free, low-toxicity immunosuppressive protocol
67. Rapamycin (AY 22,989), a new antifungal antibiotic
68. On the chemistry and high field nuclear magnetic resonance spectroscopy of Rapamycin
69. Conversion to sirolimus for liver recipients with calcineurin inhibitor toxicity
70. Orthotopic liver transplantation using low-close tacrolimus and sirolimus
71. Sirolimus: A potent new immunosuppressant for liver transplantation
72. Future of monoclonal antibodies in solid organ transplantation
73. A Phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients
74. CD28-specific antibody prevents graft-versus-host disease in mice
75. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
76. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates